Vanda Pharmaceuticals (VNDA) says that additional data from Phase III trials of the company's...

|About: Vanda Pharmaceuticals Inc. (VNDA)|By:, SA News Editor

Vanda Pharmaceuticals (VNDA) says that additional data from Phase III trials of the company's Tasimelteon treatment for Non-24-Hour Disorder "clearly demonstrate" that the medicine can train patients' master body clocks to the 24-hour day and that "continued treatment is necessary to maintain entrainment." Non-24-Hour Disorder affects most totally blind people. (PR)